Introduction
============

Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent global public health problem. CRE infections are associated with high mortality and have limited available effective treatment.[@b1-idr-12-461]--[@b3-idr-12-461] The mortality of CRE bloodstream infection was 39% in patients receiving appropriate treatment and 61% in patients receiving inappropriate treatment in a retrospective international cohort study conducted in ten countries.[@b4-idr-12-461] The growing prevalence of CRE has been reported worldwide.[@b1-idr-12-461],[@b5-idr-12-461]--[@b7-idr-12-461] A surveillance of CRE among 12,741 isolates of Enterobacteriaceae at a 2,300-bed university hospital in Bangkok, Thailand reported CRE prevalence of 1.4% during a period from 2009 to 2011.[@b8-idr-12-461] Of the 4,818 Enterobacteriaceae screening isolates, the CRE prevalence was 2.2%, and eight isolates carried carbapenemase genes in a study conducted at a university hospital in Khon Kaen, Thailand between 2010 and 2011.[@b9-idr-12-461] At our institution, CRE was first detected in December 2011. We have monitored and tracked all cases of carbapenem-non-susceptible Enterobacteriaceae since then. Despite standard infection control measures and particularly strict contact precautions, cases of CRE have substantially increased at our institution. Carbapenemases are beta-lactamase enzymes that inactivate carbapenems, and other beta-lactam antibiotics. This enzyme-mediated resistance is clinically important, as it confers high levels of carbapenem minimum inhibitory concentrations (MICs).[@b10-idr-12-461] However, ertapenem resistance in Enterobacteriaceae was mainly associated with beta-lactamases, consisting of AmpC cephalosporinases and/or extended-spectrum beta-lactamase, combined with porin deficiency.[@b11-idr-12-461],[@b12-idr-12-461] Most of these strains were resistant to ertapenem, while still moderately susceptible to imipenem and meropenem.[@b11-idr-12-461] We aim to describe CRE epidemiology at our institution, in a resource-limited setting, and to compare the phenotype of carbapenem non-susceptibility to ertapenem alone Enterobacteriaceae (NSEE) with non-susceptibility to other carbapenems (imipenem, meropenem, or doripenem) Enterobacteriaceae (NSOCE) in terms of risk factors and mortality.

Materials and methods
=====================

Study population
----------------

This retrospective cohort study was conducted at Ramathibodi Hospital, a 1,166-bed tertiary-care medical center with kidney and stem cell transplant units in Bangkok, Thailand between December 2011 and December 2016. All CRE isolated from clinical and surveillance cultures were identified from daily microbiology laboratory studies and reported to infection control units. Patients 18 years of age and older with CRE were enrolled into the comparative study.

This study was approved by the ethics institutional review boards of Ramathibodi hospital, with a waiver of informed consent.

Data collection
---------------

Demographic information, pre-existing medical conditions, intensive care unit (ICU) admission, Sequential Organ Failure Assessment (SOFA) score, mechanical ventilation, surgery, CRE colonization or infection status, microbiological, treatment, and mortality data for eligible patients were retrieved from medical records. An incident CRE case was defined as the first CRE isolate from a patient during the study period. Each patient was reviewed from 90 days prior to 90 days after the first CRE detection. Independent adjudication of patients with CRE growing in clinical cultures to determine colonization or infection status and mortality attributable to CRE was performed by two infectious diseases physicians and one physician in infectious diseases training. CRE infection was defined as CRE in blood culture; CRE isolated in sputum cultures with symptoms and signs of pneumonia, and the presence of an infiltrate on chest imaging; CRE isolated from intra-abdominal fluid, skin, soft tissue, bone, or joints with symptoms and signs of infection. A urine culture was considered to represent infection if positive with ≥10^5^ colony-forming units (CFU)/ mL with no more than two species of organisms in patients with symptoms and signs of urinary tract infection, or with no other explainable cause of fever.

All-cause mortality was assessed at 14 and 30 days after the diagnosis of CRE infections in patients who received antibiotic treatment for at least 3 days.

Antimicrobial susceptibility testing
------------------------------------

All Enterobacteriaceae isolates were tested for their susceptibility to carbapenems and other antimicrobial agents using automated microbroth dilution testing systems (Sensititre^™^; Thermo Fisher Scientific, Cleveland, OH, USA). The MIC values were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) cutoff levels.[@b13-idr-12-461] Carbapenem non-susceptibility was identified when MIC was \>1 mg/L for imipenem, meropenem, doripenem, and \>0.5 mg/L for ertapenem.

Statistical analysis
--------------------

To calculate the quarterly incidence rate from clinical and surveillance cultures of CRE, patient-days was used as the denominator. Hospital-wide carbapenem consumption were collected and calculated as defined daily doses (DDD) per 1,000 patient-days. The trend over time was estimated using a linear regression model, with time as the independent variable. Relationships between hospital-wide carbapenem consumption and incidence of CRE were tested using Poisson regression.

Comparative analysis of factors associated with NSEE and NSOCE was conducted. Chi square or Fisher's exact tests were used to compare categorical variables, as appropriate. Wilcoxon rank-sum tests were used to compare continuous variables. Logistic regression was used to estimate the odds ratios (ORs) and associated 95% CIs for factors associated with NSEE. Cox proportional hazards modeling was used to estimate the unadjusted hazard ratios (HRs) and associated 95% confidence intervals (CIs) for potential risk factors associated with 14- and 30-day mortality in patients with CRE infection who received antibiotic treatment at least 3 days following the onset of infection. Variables yielding *P*-values\<0.10 on univariate analysis, or with clinical plausibility, were included in multivariate models to identify independent predictors of mortality. The proportional hazards assumption was examined by graphically inspecting complementary log--log plots for each variable. Collinearity was checked with various inflation factors. A two-sided *P*-value of less than 0.05 was considered statistically significant for all tests. Statistical analysis was performed using Stata, version 12.0 (Stata Corp., College Station, TX, USA).

Results
=======

Incidence of CRE
----------------

The quarterly CRE incidence of unique patients increased significantly from 3.37 per 100,000 patient-days in the last quarter of 2011 to 32.49 per 100,000 patient-days in the last quarter of 2016. Quarterly CRE incidence increased 1.07 per 100,000 patient-days (95% CI=0.69--1.46; *P*-value for trend\<0.001). Quarterly hospital-wide carbapenem consumption increased 1.58 DDD per 1,000 patient-days (95% CI=0.56--2.59; *P*-value for trend=0.004). The Poisson regression showed the expected increase of CRE incidence was 1.02 per 100,000 patient-days for a 1 DDD per 1,000 patient-days increase in carbapenem consumption (95% CI=1.01--1.03; *P*-value\<0.001) ([Figure 1](#f1-idr-12-461){ref-type="fig"}).

Clinical characteristics of patients with NSEE and NSOCE
--------------------------------------------------------

A cohort of 199 unique patients with CRE isolates were identified during the study period. After exclusion of 25 pediatric patients, 174 adult patients were included in the comparative analysis. There were 40 patients with NSEE and 134 patients with NSOCE. A comparison of baseline characteristics between NSEE and NSOCE patients is shown in [Table 1](#t1-idr-12-461){ref-type="table"}. The median duration from admission to first CRE detection in NSEE group and NSOCE group was 22 days (interquartile range \[IQR\]=12--30 days) and 19 days (IQR=10--49 days), respectively. Several differences between the two groups were evident. Patients with NSEE were more likely to have intra-abdominal infection. Patients with NSOCE had higher SOFA scores, higher rates of admission to the ICU, more likelihood to be on mechanical ventilation at the time of first CRE isolation, and more exposure to carbapenems during the preceding 90 days. In the multivariate analysis, lower carbapenem exposure was significantly associated with the NSEE group (OR=0.25; 95% CI=0.11--0.56) ([Table 1](#t1-idr-12-461){ref-type="table"}).

### Microorganisms and antibiotic susceptibility of NSEE and NSOCE

The most common CRE organisms isolated in the NSOCE group were *Klebsiella pneumoniae* (70.7%) followed by *Escherichia coli* (14.0%) and *Enterobacter* species (12.7%). Among the NSEE group, the most common CRE organisms isolated were *Enterobacter* species (38.8%) followed by *E coli* (32.7%) and *K. pneumoniae* (28.6%). The most prevalent sources of CRE detection were urine, followed by intra-abdominal specimen in both groups.

The susceptibility rates to carbapenems in the NSOCE group were as follows: imipenem (23.3%), meropenem (4.0%), and doripenem (15.5%). The susceptibility rates to amikacin in the NSEE group and NSOCE groups were 81.6% and 64.9%, respectively. Overall, susceptibility rates to colistin and tigecycline were approximately 90% in both groups ([Table 2](#t2-idr-12-461){ref-type="table"}).

Analysis of risk factors associated with 14-day and 30-day all-cause mortality in CRE-infected patients
-------------------------------------------------------------------------------------------------------

Twenty-two patients (55.0%) in the NSEE group and 69 patients (51.5%) in the NSOCE group received antibiotic treatment for CRE infection. Of these, 16 patients (72.7%) in the NSEE group and 48 patients (69.5%) in the NSOCE group received in vitro active empiric treatment within the first 3 days after the onset of CRE infection. Nine patients (40.9%) in the NSEE group and 16 patients (23.2%) in the NSOCE group received monotherapy with imipenem or meropenem. Seven of these 16 patients (43.8%) in the NSOCE group received active carbapenem treatment based on in vitro susceptibility testing. The 14-day all-cause mortality in the NSEE group and the NSOCE group with CRE infection were 4.6% and 11.6%, respectively. No difference in 14-day all-cause mortality between the NSEE group and NSOCE group was observed in the univariate analysis (HR=0.37; 95% CI=0.05--2.94). The 30-day all-cause mortality in the NSEE group and NSOCE group were 9.1% and 23.2%, respectively (HR=0.43; 95% CI=0.10--1.90). Factors significantly associated with 30-day all-cause mortality in the multivariate model were chronic kidney disease, hematologic malignancies, and SOFA score ([Table 3](#t3-idr-12-461){ref-type="table"}).

Discussion
==========

The incidence of CRE clinical cultures at our institution continuously increased from 3.37 per 100,000 patient-days in the last quarter of 2011, to 7.37 per 100,000 patient-days in the last quarter of 2012, and 15.98 per 100,000 patient-days in the last quarter of 2013. This was relatively high compared to the reported incidence of CRE clinical cases of 2.94 per 100,000 population during 2012--2013 in the US,[@b1-idr-12-461] and 2.89--10.32 per 100,000 patient-days during 2010--2013 in Singapore.[@b5-idr-12-461] Furthermore, our incidence of CRE exponentially increased almost ten-fold to 32.49 per 100,000 patient-days in 2016. The standard infection control and prevention measures could not slow down the spread of CRE at our institution. More proactive infection prevention strategies are required to contain CRE. Almost 71% of NSOCE in our study were *K. pneumoniae*. This is consistent with a previous study in Thailand which found carbapenem-resistant *K. pneumoniae* (CRKP) isolates were more resistant to multiple carbapenems than other CRE species. Approximately 90% of CRE isolates in our study were susceptible to tigecycline and colistin, similar to previous studies,[@b1-idr-12-461],[@b14-idr-12-461] but unlike a previous study in Thailand which found only 47% of CRKP isolates were susceptible to tigecycline.[@b8-idr-12-461]

The main risk factors for CRE acquisition or infection were exposure to healthcare, including admission to the ICU, medical devices, invasive procedures, and antibiotics.[@b15-idr-12-461] Acquisition of CRKP was associated with poor functional status and ICU stay.[@b16-idr-12-461],[@b17-idr-12-461] Risk factors associated with CRKP infection include recent organ or stem-cell transplantation, receipt of mechanical ventilation, and longer hospital stay.[@b18-idr-12-461] Although our study found no significant healthcare exposure associated with NSOCE, there is a trend toward a longer ICU stay among NSOCE patients. Several classes of antibiotics have been associated with CRE isolation or infection, including carbapenems,[@b18-idr-12-461]--[@b20-idr-12-461] cephalosporins,[@b18-idr-12-461] fluoroquinolones,[@b16-idr-12-461],[@b19-idr-12-461] and vancomycin.[@b21-idr-12-461] We found that previous carbapenem exposure was significantly associated with NSOCE patients when compared with NSEE patients. Overall, our hospital-wide carbapenem consumption also increased, with a significant trend over time and with a significant relationship to the incidence of CRE. A meta-analysis found a strong link between antibiotic consumption and antibiotic resistance in the community. The effect of increased antibiotic usage may lead to higher resistance beyond the individual patient level.[@b22-idr-12-461] Intensive infection control measures, including early identification, rapid patient cohorting, and enhanced contact precautions, were implemented after first detection of a CRE case. Carbapenem restriction has been incorporated into electronic medical prescription at our institution since 2009, which allows empirical carbapenem use for no more than 3 days. Continuation of carbapenems after 3 days without culture-proven ESBL-producing or MDR Gram-negative bacteria must be authorized by infectious diseases or pulmonary physicians. Although our local antibiogram did not show any remarkable decrease in antibiotic susceptibility of Gram-negative bacteria, hospital-wide carbapenem consumption increased notably. One likely explanation is that certain other generic broad-spectrum antibiotics were temporarily unavailable at our institution due to suboptimal quality: cefepime was withdrawn from July to August 2014; cefepime and piperacillin/tazobactam were withdrawn from July to December 2016.

The 30-day all-cause mortality was 14% higher in the NSOCE group compared to the NSEE group. However, only chronic kidney disease, hematologic malignancies, and SOFA score remained significantly associated with the 30-day all-cause mortality following adjustment in the multivariate model. Although more carbapenems remained available for treatment based on susceptibility testing in the NSEE group, other potential factors, particularly severity of underlying medical conditions, were likely to have a stronger effect on all-cause mortality.[@b23-idr-12-461] Distinguishing CRE-related mortality from all-cause mortality posed a challenge. Mechanisms of resistance in ertapenem-resistant but imipenem-susceptible *K. pneumoniae* have been demonstrated to be predominantly mediated by non-carbapenemase mechanisms, including defect in porins OmpK35 and OmpK36 expression,[@b11-idr-12-461],[@b12-idr-12-461] SHV-type ESBLs, and the DHA-1-type AmpC beta-lactamases in comparison to imipenem-non-susceptible *K. pneumoniae* isolates.[@b24-idr-12-461] A study of molecular characterization was done to identify the mechanisms of resistance of NSEE and NSOCE at our institution during 2012--2016. It found that 78% of the CRE carried carbapenemase genes. The *bla*NDM-1 was the most common resistant gene, accounting for almost 70% of all CRE isolates, followed by the *bla*OXA-48-like group. Only 3% was *bla*IMP-14, and no *bla*~KPC~ was detected.[@b25-idr-12-461] In another study, only 1.4% of CRE isolates carried at least one carbapenemase gene, and the most common genes were *bla*KPC-13 and *bla*IMP-14a in a previous study at another institution in Thailand during 2009--2011.[@b8-idr-12-461] Although NSEE isolates were phenotypically susceptible to imipenem and meropenem, the underlying resistance mechanism is important for selecting appropriate antibiotic treatment.[@b26-idr-12-461] Treatment with carbapenems was not recommended for *bla*NDM-1 and *bla*OXA-48 producers.[@b26-idr-12-461] There was 23% more carbapenem monotherapy in the NSEE group than the NSOCE group, while both groups had similar carbapenemases. This might affect mortality for CRE-infected patients treated with carbapenems in our study. However, our study may have been underpowered due to the small number of subjects enrolled.

This study has several limitations. First, we were unable to complete 30-day follow-up after first CRE detection in 49 patients (28.1%), which led to censoring bias and survival bias. We used a Cox model to account for censoring bias. Although we could not eliminate survival bias, the analysis excluding these 49 patients did not significantly change the overall results. Second, as our setting is a tertiary care hospital, it might not be representative of other hospitals with different prevalence of Gram-negative drug resistance. Lastly, comparisons of risk factors and treatment outcome were made as NSEE vs NSOCE. Further comparisons of CRE vs non-CRE patients may illustrate more distinctions of different patterns of antibiotic resistance.

Conclusion
==========

The incidence of CRE has risen significantly over a 5-year period at our institution. The important risk factor for non-susceptibility to other carbapenems compared to non-susceptibility to ertapenem alone was previous carbapenem use. Our hospital-wide carbapenem use has significantly increased over time, and is associated with the increasing incidence of CRE. Emphasis on antimicrobial stewardship could be an effective strategy to slow down the rising CRE trends.
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**Abbreviations:** CRE, carbapenem-resistant Enterobacteriaceae; DDD, defined daily doses; NSEE, carbapenem non-susceptibility to ertapenem alone Enterobacteriaceae; NSOCE, non-susceptibility to other carbapenems (imipenem, meropenem, or doripenem) Enterobacteriaceae.](idr-12-461Fig1){#f1-idr-12-461}

###### 

Baseline characteristics of 174 adult patients with CRE and comparative analysis of NSEE and NSOCE

                                                                                                        Univariate analysis   Multivariate analysis[a](#tfn1-idr-12-461){ref-type="table-fn"}                       
  --------------------------------------------------------------- ------------- ------------- --------- --------------------- ----------------------------------------------------------------- ------------------- -------
  Age (years), median (IQR)                                       64 (55--73)   71 (54--78)   0.24      0.99 (0.97--1.01)     0.40                                                                                  
  Male                                                            21 (52.5%)    58 (43.3%)    0.30      0.69 (0.34--1.40)     0.31                                                                                  
  **Previous admission within 90 days**                                                       0.59                                                                                                                  
  No previous admission                                           20 (50.0%)    63 (47.0%)                                                                                                                          
  Same hospital                                                   15 (37.5%)    60 (44.8%)                                                                                                                          
  Outside hospital                                                5 (12.5%)     11 (8.2%)                                                                                                                           
  **Pre-existing medical conditions**                                                                                                                                                                               
  Chronic pulmonary disease                                       0 (0%)        9 (6.7%)      0.12      0.16 (0.01--2.86)     0.21                                                                                  
  Cardiovascular disease                                          8 (20.0%)     30 (22.4%)    0.75      0.87 (0.36--2.08)     0.75                                                                                  
  Chronic liver disease                                           0 (0%)        7 (5.2%)      0.35      0.21 (0.01--3.76)     0.29                                                                                  
  Chronic kidney disease                                          5 (12.5%)     18 (13.4%)    0.88      0.92 (0.32--2.66)     0.88                                                                                  
  Neurologic disease                                              3 (7.5%)      21 (15.7%)    0.29      0.44 (0.12--1.55)     0.20                                                                                  
  Diabetes mellitus                                               11 (27.5%)    49 (36.6%)    0.29      0.66 (0.30--1.43)     0.29                                                                                  
  Solid tumor                                                     18 (45.0%)    45 (33.6%)    0.19      1.62 (0.79--3.32)     0.19                                                                                  
  Hematologic malignancies                                        4 (10.0%)     15 (11.2%)    \>0.99    0.88 (0.28--2.82)     0.83                                                                                  
  HIV                                                             0 (0%)        2 (1.5%)      \>0.99                                                                                                                
  Chemotherapy in 6 months                                        6 (15.0%)     17 (12.7%)    0.71      1.21 (0.44--3.32)     0.71                                                                                  
  Immunomodulatory therapy or corticosteroids for ≥14 days        3 (7.5%)      12 (9.0%)     \>0.99    0.82 (0.22--3.08)     0.77                                                                                  
  SOFA score, median (IQR)                                        2 (1--5)      4 (2--7)      0.007     0.88 (0.79--0.98)     0.02                                                              0.98 (0.87--1.11)   0.77
  **Epidemiological risks**                                                                                                                                                                                         
  Time from admission to CRE detection, days, median (IQR)        22 (12--30)   19 (10--49)   0.64      0.99 (0.98--1.00)     0.13                                                                                  
  In ICU at the time of culture                                   7 (17.5%)     53 (39.6%)    0.01      0.32 (0.13--0.79)     0.01                                                              0.39 (0.13--1.16)   0.09
  On mechanical ventilation                                       13 (32.5%)    80 (59.7%)    0.002     0.33 (0.15--0.69)     0.003                                                             0.63 (0.24--1.64)   0.35
  Central venous line                                             7 (17.5%)     26 (19.4%)    0.79      0.88 (0.35--2.21)     0.79                                                                                  
  Hemodialysis                                                    6 (15.0%)     29 (21.6%)    0.36      0.64 (0.24--1.67)     0.36                                                                                  
  Surgery in the preceding 90 days                                26 (65.0%)    70 (52.2%)    0.15      1.70 (0.82--3.53)     0.16                                                                                  
  **Co-colonization with other MDROs during preceding 90 days**                                                                                                                                                     
  ESBL Gram-negative                                              11 (27.5%)    56 (41.8%)    0.10      0.53 (0.24--1.15)     0.11                                                                                  
  *Acinetobacter baumannii*                                       3 (7.5%)      21 (15.7%)    0.29      0.44 (0.12--1.55)     0.2                                                                                   
  *Pseudomona aeruginosa*                                         0 (0%)        8 (6.0%)      0.21      0.18 (0.01--3.25)     0.25                                                                                  
  MRSA                                                            0 (0%)        11 (8.2%)     0.07      0.13 (0.01--2.30)     0.17                                                                                  
  VRE                                                             1 (2.5%)      3 (2.2%)      \>0.99    1.12 (0.11--11.07)    0.92                                                                                  
  **Previous antibiotic exposure within 90 days**                                                                                                                                                                   
  Carbapenems                                                     15 (37.5%)    93 (69.4%)    \<0.001   0.26 (0.13--0.55)     \<0.001                                                           0.25 (0.11--0.56)   0.001
  Ceftriaxone                                                     12 (30.0%)    51 (38.1%)    0.35      0.70 (0.33--1.49)     0.35                                                                                  
  Cefepime                                                        4 (10.0%)     12 (9.0%)     0.76      1.13 (0.34--3.72)     0.84                                                                                  
  Piperacillin/tazobactam                                         15 (37.5%)    51 (38.1%)    0.95      0.98 (0.47--2.02)     0.95                                                                                  
  Fluoroquinolones                                                14 (35.0%)    36 (26.9%)    0.32      1.47 (0.69--3.11)     0.32                                                                                  
  Aminoglycosides                                                 2 (5.0%)      12 (9.0%)     0.53      0.54 (0.11--2.50)     0.43                                                                                  
  **Type of identification**                                                                                                                                                                                        
  Colonization                                                    18 (45.0%)    62 (46.3%)    0.89      0.95 (0.47--1.93)     0.89                                                                                  
  Primary bacteremia                                              1 (2.5%)      14 (10.5%)    0.20      0.22 (0.03--1.73)     0.15                                                                                  
  Pneumonia                                                       1 (2.5%)      12 (9.0%)     0.30      0.26 (0.03--2.07)     0.20                                                                                  
  Skin and soft tissue infection                                  3 (7.5%)      8 (6.0%)      0.72      1.28 (0.32--5.06)     0.73                                                                                  
  Urinary tract infection                                         5 (12.5%)     19 (14.2%)    0.79      0.86 (0.30--2.48)     0.79                                                                                  
  Intra-abdominal infection                                       12 (30.0%)    21 (15.7%)    0.04      2.30 (1.01--5.24)     0.046                                                             2.46 (0.96--6.31)   0.06

**Note:**

Adjusted for variables with *P*\<0.10 in univariate analysis.

**Abbreviations:** CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended spectrum beta-lactamases; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range; MDROs, multidrug-resistant organisms; MRSA, methicillin-resistant *Staphylococcus aureus*; OR, odds ratio; SOFA, Sequential Organ Failure Assessment; VRE, vancomycin-resistant enterococci.

###### 

Microorganisms and antibiotic susceptibility profiles of NSEE and NSOCE isolates, December 2011 to December 2016

                                                                      NSEE (N=49)   NSOCE (N=150)
  ------------------------------------------------------------------- ------------- ---------------
  **Bacterial species**                                                             
  *Klebsiella pneumoniae*                                             14 (28.6%)    106 (70.7%)
  *Escherichia coli*                                                  16 (32.7%)    21 (14.0%)
  *Enterobacter* spp.                                                 19 (38.8%)    19 (12.7%)
  Other (*Citrobacter* spp., *Proteus* spp., *Serratia marcescens*)   0 (0%)        4 (2.7%)
  **Source**                                                                        
  Urine                                                               19 (38.8%)    69 (46.0%)
  Intra-abdominal                                                     16 (32.7%)    32 (21.3%)
  Respiratory specimens                                               6 (12.2%)     17 (11.3%)
  Wound swab                                                          6 (12.2%)     18 (12.0%)
  Blood                                                               2 (4.1%)      14 (9.3%)
  **Amikacin (no. of isolates tested**)                               49            148
  Susceptible, n                                                      40 (81.6%)    96 (64.9%)
  Intermediate, n                                                     2 (4.1%)      1 (0.7%)
  Resistant, n                                                        7 (14.3%)     51 (34.5%)
  **Gentamicin (no. of isolates tested**)                             49            148
  Susceptible, n                                                      22 (44.9%)    56 (37.8%)
  Intermediate, n                                                     1 (2.0%)      5 (3.4%)
  Resistant, n                                                        26 (53.1%)    87 (58.8%)
  **Colistin (no. of isolates tested**)                               49            148
  Susceptible, n                                                      46 (93.9%)    137 (92.6%)
  Intermediate, n                                                     0 (0%)        0 (0%)
  Resistant, n                                                        3 (6.1%)      11 (7.4%)
  **Tigecycline (no. of isolates tested**)                            49            148
  Susceptible, n                                                      44 (89.8%)    135 (91.2%)
  Intermediate, n                                                     3 (6.1%)      7 (4.7%)
  Resistant, n                                                        2 (4.1%)      6 (4.1)
  **Imipenem (no. of isolates tested**)                               49            150
  Susceptible, n                                                      49 (100%)     35 (23.3%)
  Intermediate, n                                                     0 (0%)        20 (13.3%)
  Resistant, n                                                        0 (0%)        95 (63.3%)
  **Meropenem (no. of isolates tested**)                              49            150
  Susceptible, n                                                      49 (100%)     6 (4.0%)
  Intermediate, n                                                     0 (0%)        18 (12.0%)
  Resistant, n                                                        0 (0%)        126 (84.0%)
  **Doripenem (no. of isolates tested**)                              49            148
  Susceptible, n                                                      49 (100%)     23 (15.5%)
  Intermediate, n                                                     0 (0%)        27 (18.2%)
  Resistant, n                                                        0 (0%)        98 (66.2%)
  **Piperacillin/tazobactam (no. of isolates tested**)                49            147
  Susceptible, n                                                      8 (16.3%)     6 (4.1%)
  Intermediate, n                                                     4 (8.2%)      10 (6.8%)
  Resistant, n                                                        37 (75.5%)    131 (89.1%)
  **Amoxicillin/clavulanate (no. of isolates tested**)                49            145
  Susceptible, n                                                      3 (6.1%)      1 (0.7%)
  Intermediate, n                                                     9 (18.4%)     11 (7.6%)
  Resistant, n                                                        37 (75.5%)    133 (91.7%)
  **Ciprofloxacin (no. of isolates tested**)                          49            148
  Susceptible, n                                                      9 (18.4%)     15 (10.1%)
  Intermediate, n                                                     2 (4.1%)      6 (4.1%)
  Resistant, n                                                        28 (57.1%)    127 (85.8%)
  **Levofloxacin (no. of isolates tested**)                           49            146
  Susceptible, n                                                      11 (22.4%)    23 (15.8%)
  Intermediate, n                                                     5 (10.2%)     10 (6.8%)
  Resistant, n                                                        33 (67.3%)    113 (77.4%)

**Abbreviations:** NSEE, carbapenem nonsusceptibility to ertapenem alone Enterobacteriaceae; NSOCE, non-susceptibility to other carbapenems (imipenem, meropenem, or doripenem) Enterobacteriaceae.

###### 

Thirty-day all-cause mortality for adult patients with CRE infections

  Variables                                                            Unadjusted HR (95% CI)   *P*-value   Adjusted HR[a](#tfn4-idr-12-461){ref-type="table-fn"} (95% CI)   *P*-value
  -------------------------------------------------------------------- ------------------------ ----------- ---------------------------------------------------------------- -----------
  Non-susceptibility to ertapenem alone                                0.43 (0.10--1.90)        0.27                                                                         
  Chronic kidney disease                                               5.68 (1.99--16.25)       0.001       4.12 (1.02--16.63)                                               0.046
  Solid tumor                                                          0.31 (0.09--1.08)        0.07        0.51 (0.13--2.05)                                                0.35
  Hematologic malignancies                                             6.95 (2.61--18.50)       \<0.001     6.84 (1.86--25.12)                                               0.004
  SOFA score                                                           1.28 (1.16--1.41)        \<0.001     1.22 (1.06--1.41)                                                0.007
  In ICU at the time of culture                                        2.46 (0.93--6.47)        0.07        1.45 (0.43--4.90)                                                0.55
  On mechanical ventilation                                            2.57 (0.84--7.88)        0.10        0.80 (0.20--3.21)                                                0.75
  Primary bacteremia                                                   3.33 (1.23--9.03)        0.02        1.36 (0.39--4.70)                                                0.63
  In vitro active empiric treatment in the first 3 days of infection   1.97 (0.56--6.84)        0.29                                                                         

**Notes:**

Adjusted for variables with *P*\<0.10 in univariate analysis.

**Abbreviations:** CRE, carbapenem-resistant Enterobacteriaceae; HR, hazard ratio; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.
